Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMD Serono Research & Development Institute, Inc.
With
Merck KGaA, Darmstadt, Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants who have an Eastern Cooperative Oncology Group Performance Status less than or equals to (\<=) 1
Participants who have histologically confirmed and localized resectable rectal cancer (Stage 3)
Participants who received induction chemotherapy are allowed to be enrolled to this study except this induction is resulting in clinical complete response (cCR) or tumor progression
Participants who have lower edge of the tumor located in rectum
Adequate hematological, hepatic and renal function as defined in the protocol
Male participants if they agree to the following during the study intervention period and for at least 12 weeks after the last dose of study intervention
You may not be if
Participants with history of any other significant medical disease or psychiatric conditions that might in the assessment of the Investigator preclude safe participation in the study
Participants with history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the study intervention
Unstable cardiovascular function within 6 months prior to enrollment
Hypertension uncontrolled by medication (ie, systolic blood pressure \>= 150 millimeter of mercury (mmHg) and diastolic blood pressure \>= 90 mmHg)
Participants with history of other malignant disease within the past 5 years, other than successfully treated basal carcinoma of the skin or carcinoma in situ of the cervix
Participants with known human immunodeficiency virus positivity, known active hepatitis (for example, hepatitis B virus or hepatitis C virus), current alcohol abuse, or cirrhosis
Participants with ongoing active infection or treatment with a live attenuated vaccine within 4 weeks of dosing
Participants with concomitant use of H2-blocker or proton pump inhibitors (PPIs) (or unable to stop at least 5 days prior to the first treatment). Note that calcium carbonate is acceptable
Participation in any interventional clinical study within 28 days prior to Screening or during participation in this study
